Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1718039 | 1.00 | ALOX15 (0.43) | ALOX15GRIK2HDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL1718035 | 1.00 | ALOX15 (0.43) | ALOX15GRIK2HDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL28833784 | 1.00 | ALOX15 (0.43) | ALOX15GRIK2HDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL28833830 | 1.00 | ALOX15 (0.43) | ALOX15GRIK2HDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL6635115 | 1.00 | ALOX15 (0.43) | ALOX15GRIK2HDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL16821111 | 0.87 | GBA1 (0.44) | ALOX15GRIK2HDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL14762269 | 0.87 | GBA1 (0.44) | ALOX15GRIK2HDAC4SMN1; SMN2NPSR1 | |
| SCHEMBL199463 | 0.81 | SLC1A2 (0.47) | HDAC4AKR1C3AKR1C1 | |
| SCHEMBL199461 | 0.81 | SLC1A2 (0.47) | HDAC4AKR1C3AKR1C1 | |
| SCHEMBL350996 | 0.81 | SLC1A2 (0.47) | HDAC4AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212788-A1 | NEW METHOD FOR AUTOMATED ON-DEMAND BIOMOLECULAR ARRAY SYNTHESIS | Technische Universität Dresden (DE) | 2023-07-06 | — | — | US | disclosed |
| EP-4127718-A1 | NEW METHOD FOR AUTOMATED ON-DEMAND BIOMOLECULAR ARRAY SYNTHESIS | Technische Universität Dresden (DE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115698714-A | Novel method for automated on-demand biomolecule array synthesis | 德累斯顿工业大学 | 2023-02-03 | — | — | CN | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| WO-2021191247-A1 | NEW METHOD FOR AUTOMATED ON-DEMAND BIOMOLECULAR ARRAY SYNTHESIS | Technische Universität Dresden (DE) | 2021-09-30 | — | — | WO | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-8293776-B2 | Compositions and methods for treating inflammatory conditions of the bowel | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-10-23 | — | — | US | disclosed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20040058876-A1 | Secondary binding site of dipeptidyl peptidase IV (DP IV) | PROSIDION LIMITED (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1399469-A2 | PEPTIDE STRUCTURES USEFUL FOR COMPETITIVE MODULATION OF DIPEPTIDYL PEPTIDASE IV CATALYSIS | Probiodrug AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030176357-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | PROSIDION LIMITED (GB) | 2003-09-18 | — | — | US | disclosed |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | PROSIDION LIMITED (GB) | 2003-08-07 | — | — | US | disclosed |
| US-20030135023-A1 | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis | PROSIDION LIMITED (GB) | 2003-07-17 | — | — | US | disclosed |
| US-20030125304-A1 | Substituted amino ketone compounds | PROSIDION LIMITED (GB) | 2003-07-03 | — | — | US | disclosed |
| US-20030119738-A1 | Novel inhibitors of dipeptidyl peptidase I | PROBLODRUG AG (DE) | 2003-06-26 | — | — | US | disclosed |
| US-20030119736-A1 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| WO-2003002593-A2 | PEPTIDE STRUCTURES USEFUL FOR COMPETITIVE MODULATION OF DIPEPTIDYL PEPTIDASE IV CATALYSIS | PROBIODRUG AG (DE) | 2003-01-09 | — | — | WO | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ALOX15 2548/4885GRIK2 4390/4885HDAC4 1812/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ALOX15 2548/4885GRIK2 4390/4885HDAC4 1812/4885 |
| US-20030148961-A1 | Peptidyl ketones as inhibitors of DPIV | GLS, SLC5A1, BCKDK | ALOX15 1543/4885GRIK2 2678/4885HDAC4 3061/4885 |
| US-20030135023-A1 | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis | PEPD, DNPEP, ANPEP | ALOX15 3761/4885GRIK2 3019/4885HDAC4 1380/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ALOX15 2548/4885GRIK2 4390/4885HDAC4 1812/4885 |
| US-20040058876-A1 | Secondary binding site of dipeptidyl peptidase IV (DP IV) | DPP4, DPP3, DPP7 | ALOX15 3491/4885GRIK2 3375/4885HDAC4 1087/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ALOX15 2548/4885GRIK2 4390/4885HDAC4 1812/4885 |
| US-20030125304-A1 | Substituted amino ketone compounds | SLC5A1, GLS, GPR119 | ALOX15 1262/4885GRIK2 1052/4885HDAC4 3697/4885 |
| US-20030119736-A1 | Methods for improving islet signaling in diabetes mellitus and for its prevention | IAPP, GLP1R, GPR119 | ALOX15 1840/4885GRIK2 3666/4885HDAC4 906/4885 |
| US-20030176357-A1 | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | DPP4, DPP3, DPP9 | ALOX15 3631/4885GRIK2 3269/4885HDAC4 438/4885 |
| US-20030119738-A1 | Novel inhibitors of dipeptidyl peptidase I | CTSC, DPP9, DPP3 | ALOX15 2505/4885GRIK2 3422/4885HDAC4 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.